NOVAVAX INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
NOVAVAX INC (NVAX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $8.20 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $8.20M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $4.00M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $1.30M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $6.10M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $8.20M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $4.00M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.30M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.10M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $800.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $900.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $3.20M 10-K · filed 2025-02-27 |
| 2024-09-30 | $11.60M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $12.30M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $100.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $100.00K 10-K · filed 2024-02-28 |
| 2023-09-30 | $1.40M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.70M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $900.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $3.00M 10-K · filed 2023-02-28 |
| 2022-09-30 | $9.00M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $91.00M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $154.00M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $376.00M 10-K · filed 2022-03-01 |
| 2021-09-30 | $673.00M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $865.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $738.00M 10-Q · filed 2021-05-10 |
| 2020-09-30 | $446.50M 10-Q · filed 2020-11-10 |
| 2015-03-31 | $81.40M 10-Q · filed 2015-05-07 |
| 2014-09-30 | $25.80M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $31.10M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $30.30M 10-Q · filed 2014-05-08 |
| 2013-09-30 | $15.90M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $4.30M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $6.60M 10-Q · filed 2013-05-09 |
| 2012-09-30 | $4.60M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $1.50M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |